Bank of New York Mellon Corp - OCULAR THERAPEUTIX INC ownership

OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 70 filers reported holding OCULAR THERAPEUTIX INC in Q2 2019. The put-call ratio across all filers is 1.35 and the average weighting 0.8%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of OCULAR THERAPEUTIX INC
ValueSharesWeighting
Q3 2023$754,574
-50.2%
240,310
-18.1%
0.00%
Q2 2023$1,514,006
-1.0%
293,412
+1.2%
0.00%
Q1 2023$1,528,591
+104.2%
290,055
+8.9%
0.00%
Q4 2022$748,461
-33.4%
266,356
-1.6%
0.00%
Q3 2022$1,123,000
+12.2%
270,610
+8.7%
0.00%
Q2 2022$1,001,000
-23.1%
249,018
-5.3%
0.00%
Q1 2022$1,302,000
-28.5%
263,040
+0.7%
0.00%
Q4 2021$1,820,000
-26.1%
261,157
+6.0%
0.00%
Q3 2021$2,464,000
-20.5%
246,337
+12.7%
0.00%
-100.0%
Q2 2021$3,098,000
-26.8%
218,505
-15.3%
0.00%0.0%
Q1 2021$4,232,000
-36.8%
257,917
-20.2%
0.00%0.0%
Q4 2020$6,693,000
+369.4%
323,311
+72.4%
0.00%
Q3 2020$1,426,000
+1.4%
187,500
+11.2%
0.00%
Q2 2020$1,406,000
+130.5%
168,667
+36.8%
0.00%
Q1 2020$610,000
+29.0%
123,332
+3.1%
0.00%
Q4 2019$473,000
+38.7%
119,669
+6.6%
0.00%
Q3 2019$341,000
-26.5%
112,272
+6.5%
0.00%
Q2 2019$464,000
+14.0%
105,467
+2.9%
0.00%
Q1 2019$407,000
+3.0%
102,477
+3.3%
0.00%
Q4 2018$395,000
-39.1%
99,190
+5.2%
0.00%
Q3 2018$649,000
+2.0%
94,2940.0%0.00%
Q2 2018$636,000
+17.6%
94,294
+13.6%
0.00%
Q1 2018$541,000
+75.1%
83,018
+19.8%
0.00%
Q4 2017$309,000
-38.7%
69,319
-15.0%
0.00%
Q3 2017$504,000
-33.2%
81,586
+0.2%
0.00%
Q2 2017$755,000
-8.4%
81,420
-8.2%
0.00%
Q1 2017$824,000
+38.5%
88,736
+24.9%
0.00%
Q4 2016$595,000
+2.9%
71,057
-15.6%
0.00%
Q3 2016$578,000
+108.7%
84,199
+50.6%
0.00%
Q2 2016$277,000
-52.7%
55,915
-8.0%
0.00%
Q1 2016$586,000
-7.7%
60,747
-10.4%
0.00%
Q4 2015$635,000
-37.9%
67,831
-6.7%
0.00%
Q3 2015$1,023,000
-9.5%
72,724
+35.2%
0.00%
Q2 2015$1,131,000
+23.7%
53,782
+147.0%
0.00%
Q1 2015$914,000
+124.6%
21,776
+26.0%
0.00%
Q4 2014$407,000
+108.7%
17,288
+33.2%
0.00%
Q3 2014$195,00012,9790.00%
Other shareholders
OCULAR THERAPEUTIX INC shareholders Q2 2019
NameSharesValueWeighting ↓
SUMMER ROAD LLC 6,122,089$31,590100.00%
Opaleye Management Inc. 5,780,000$29,824,8007.13%
DELTEC ASSET MANAGEMENT LLC 1,974,797$10,189,9532.23%
Lynwood Capital Management Inc. 262,500$1,354,5001.72%
Endurant Capital Management LP 368,438$1,901,1401.66%
Knoll Capital Management, LLC 200,000$1,032,0001.25%
Knoll Capital Management, LLC 95,800$814,3000.99%
SECTORAL ASSET MANAGEMENT INC 802,680$4,141,8290.69%
ESSEX INVESTMENT MANAGEMENT CO LLC 300,977$1,553,0410.22%
Cormorant Asset Management, LP 645,000$3,328,2000.19%
View complete list of OCULAR THERAPEUTIX INC shareholders